Related Experiment Video
Updated: May 26, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
[S-1/krestin immunochemotherapy for patients with advanced gastric cancer]
Toru Aoyama1, Takaki Yoshikawa, Tsutomu Hayashi
1Dept. of Gastrointestinal Surgery, Kanagawa Cancer Center.
Background:
S-1 mono-therapy for advanced gastric cancer is hard to continue in some patients due to adverse events. We retrospectively examined the patients who received S-1/Krestin( PSK) immunochemotherapy for advanced gastric cancer.
Methods:
During September 2006 to August 2008, 3 patients had received S-1/PSK. S-1 was given for 6-week schedule or 3-week schedule, and PSK was for everyday during the S-1 treatment.
Results:
Cases 1 and 2 had lymph node metastases after surgery. Case 3 had peritoneal metastasis. The median treatment duration was 112 days. The median overall survival was 552 days. All patients stopped the treatment due to progression of disease. There were no patients who stopped the treatment due to adverse events.
Conclusions:
PSK may increase the compliance of S-1.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers